Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab ...
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...
Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...
Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a ...
The U.S. Food and Drug Administration (FDA) has approved for review a Biologics License Application (BLA) for AVT06, Alvotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback